Situation

GRA worked in partnership with a European vaccine development company to lead an application for a £3 million SBRI contract funded by the UK’s Department of Health.  The funds were intended for identification of a correlate of protection to enable phase III studies using clinical and preclinical studies relating to a Chikungunya vaccine.

GRA Involvement

• Scoping of Chikungunya scientific, commercial and IP landscape
• Generation and management of application
• Led application for government based funding
• Development of Chikungunya CMC, preclinical and clinical project plan
• Interaction with UK’s Innovate UK (SBRI)

Value Added

GRA worked with the vaccine company to assemble a business case for the further development of a Chikungunya vaccine and justify how the funding could accelerate the program into phase III clinical trials.  This case was put forward to the SBRI review panel. After a final interview panel, the application was confirmed as successful in June 2017.   The project is being performed over a period of 3 year period.  GRA successfully helped lead the application to raise £3 million in non-dilutional funding to develop the vaccine.  GRA is also project managing the contract.  Read the press release here.